Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Kymera Therapeutics Inc.

    NASDAQ: KYMR · Real-Time Price · USD
    47.16
    0.87 (1.88%)
    At close: Jun 24, 2025, 3:59 PM
    45.50
    -3.52%
    Pre-market: Jun 25, 2025, 07:50 AM EDT

    Kymera Therapeutics Statistics

    Share Statistics

    Kymera Therapeutics has 65.12M shares outstanding. The number of shares has increased by 5.84% in one year.

    Shares Outstanding

    n/a
    		 65.12M

    Shares Change (YoY)

    n/a
    		 5.84%

    Shares Change (QoQ)

    n/a
    		 0.28%

    Owned by Institutions (%)

    n/a
    		 94.21%

    Shares Floating

    n/a
    		 53.16M

    Failed to Deliver (FTD) Shares

    n/a
    		 3

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 6.59M, so 10.12% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.59M

    Short % of Shares Out

    n/a
    		 10.12%

    Short % of Float

    n/a
    		 12.78%

    Short Ratio (days to cover)

    n/a
    		 10.49

    Valuation Ratios

    The PE ratio is -13.49 and the forward PE ratio is -11.98. Kymera Therapeutics's PEG ratio is -0.74.

    PE Ratio

    n/a
    		 -13.49

    Forward PE

    n/a
    		 -11.98

    PS Ratio

    n/a
    		 64.14

    Forward PS

    n/a
    		 5.3

    PB Ratio

    n/a
    		 3.61

    P/FCF Ratio

    n/a
    		 -14.56

    PEG Ratio

    n/a
    		 -0.74
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Kymera Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.53, with a Debt / Equity ratio of 0.11.

    Current Ratio

    n/a
    		 7.53

    Quick Ratio

    n/a
    		 7.53

    Debt / Equity

    n/a
    		 0.11

    Debt / EBITDA

    n/a
    		 -0.41

    Debt / FCF

    n/a
    		 -0.42

    Interest Coverage

    n/a
    		 -1050.74

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $226,307.69

    Profits Per Employee

    n/a
    		 $-1,076,240.38

    Employee Count

    n/a
    		 208

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 51.4% in the last 52 weeks. The beta is 2.07, so Kymera Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.07

    52-Week Price Change

    n/a
    		 51.4%

    50-Day Moving Average

    n/a
    		 35.36

    200-Day Moving Average

    n/a
    		 39.47

    Relative Strength Index (RSI)

    n/a
    		 70.29

    Average Volume (20 Days)

    n/a
    		 877,837

    Income Statement

    In the last 12 months, Kymera Therapeutics had revenue of 47.07M and earned -223.86M in profits. Earnings per share was -2.98.

    Revenue

    n/a
    		 47.07M

    Gross Profit

    n/a
    		 47.07M

    Operating Income

    n/a
    		 -261.63M

    Net Income

    n/a
    		 -223.86M

    EBITDA

    n/a
    		 -216.24M

    EBIT

    n/a
    		 -223.61M

    Earnings Per Share (EPS)

    n/a
    		 -2.98
    Full Income Statement

    Balance Sheet

    The company has 120.26M in cash and 87.76M in debt, giving a net cash position of 32.49M.

    Cash & Cash Equivalents

    n/a
    		 120.26M

    Total Debt

    n/a
    		 87.76M

    Net Cash

    n/a
    		 32.49M

    Retained Earnings

    n/a
    		 -754.61M

    Total Assets

    n/a
    		 918.31M

    Working Capital

    n/a
    		 441.96M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -194.5M and capital expenditures -12.84M, giving a free cash flow of -207.34M.

    Operating Cash Flow

    n/a
    		 -194.5M

    Capital Expenditures

    n/a
    		 -12.84M

    Free Cash Flow

    n/a
    		 -207.34M

    FCF Per Share

    n/a
    		 -2.76
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -555.82% and -475.57%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -555.82%

    Pretax Margin

    n/a
    		 -475.57%

    Profit Margin

    n/a
    		 -475.57%

    EBITDA Margin

    n/a
    		 -459.37%

    EBIT Margin

    n/a
    		 -555.82%

    FCF Margin

    n/a
    		 -440.47%

    Dividends & Yields

    KYMR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for KYMR is $58.5, which is 24% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $58.5

    Price Target Difference

    n/a
    		 24%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 17
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 12.5

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist